RxDoctor Payments Data

Whitney Albright, PA

Medical · Southern Pines, NCNPI 1083951610

Payments from drug & device makers

$2,332in general payments, 2019–2025

Across 54 payments — averaging $43.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$534
  • Boston Scientific$479
  • SPR Therapeutics, Inc$302
  • Vertos Medical, Inc.$288
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$165
  • Collegium Pharmaceutical, Inc.$133
  • plus $431 from 11 others

What the payments were for

  • Food & beverage$2,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 75th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,354
Medicare patients
192
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate101$51,232
RelistorMethylnaltrexone Bromide18$40,484
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,099$38,059
BelbucaBuprenorphine Hcl48$36,886
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen871$21,972
OxycontinOxycodone Hcl34$17,528
LinzessLinaclotide12$17,485
Oxycodone Hcl581$13,262
Buprenorphine56$12,550
Fentanyl76$10,179
Pregabalin221$9,146
Gabapentin390$7,784
Lidocaine37$6,330
MovantikNaloxegol Oxalate13$6,035
Naloxone Hcl57$5,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$133$88,118149 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$165$40,48418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 medical providers in North Carolina.

Other medical in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →